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Abstract
Background: Myeloid ecotropic viral integration site 1 (MEIS1) protein plays a synergistic causative role in
acute myeloid leukemia (AML). However, MEIS1 has also shown to be a potential tumor suppressor in some
other cancers, such as non-small-cell lung cancer (NSCLC) and prostate cancer. Although multiple roles of
MEIS1 in cancer development and progression have been identified, there is an urgent demand to discover
more functions of this molecule for further therapeutic design.
Methods: MEIS1 was overexpressed via adenovirus vector in clear cell renal cell carcinoma (ccRCC) cells.
Western blot and real-time qPCR (quantitative Polymerase Chain Reaction) was performed to examine the
protein and mRNA levels of MEIS1. Cell proliferation, survival, in vitro migration and invasion were tested by
MTT, colony formation, soft-agar, transwell (in vitro invasion/migration) assays, and tumor in vivo growthwas
measured on nude mice model. In addition, flow-cytometry analysis was used to detect cell cycle arrest or
non-apoptotic cell death of ccRCC cells induced by MEIS1.
Results: MEIS1 exhibits a decreased expression in ccRCC cell lines than that in non-tumor cell lines. MEIS1 overexpression
inhibits ccRCC cells proliferation and induces G1/S arrest concomitant with marked reduction of G1/S transition regulators,
Cyclin D1 and Cyclin A. Moreover, MEIS1-1 overexpression also induces non-apoptotic cell death of ccRCC cells via
decreasing the levels of pro-survival regulators Survivin and BCL-2. Transwell migration assay (TMA) shows that MEIS1
attenuates in vitro invasion and migration of ccRCC cells with down-regulated epithelial-mesenchymal transition (EMT)
process. Further, in nude mice model, MEIS1 inhibits the in vivo growth of Caki-1 cells.
Conclusions: By investigating the role of MEIS1 in ccRCC cells’ survival, proliferation, anchorage-independent growth,
cell cycle progress, apoptosis and metastasis, in the present work, we propose that MEIS1 may play an important role
in clear cell renal cell carcinoma (ccRCC) development.
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Background
As a member of TALE (Triple amino acid loop extension)
transcription factors, MEIS1 contains a homeodomain
which is generally recognized be important for its roles in
cell growth and differentiation during vertebrate embryo-
genesis [1–3]. MEIS1 also plays a critical role in develop-
ment and stem cells regulation [4–6]. Various genetic
alterations occur in AML that lead to overexpression of
the MEIS/HOXA9 complex, which plays a synergistic
causative role in acute myeloid leukemia (AML) develop-
ment [7–10]. However, a range of recent work also
revealed that MEIS1 would also be found as a negative
regulator in some other cancers, e.g. non-small-cell lung
cancer or prostate cancer [11–13]. In these cancers,
MEIS1 would function via inhibiting cell proliferation and
inducing cell cycle arrest [11–13]. High level of MEIS1
was detected in normal prostate compared with prostate
tumor tissues; indicating that it would be a useful
biomarker or even a therapeutic target of human prostate
carcinoma [13]. Rad et al reported that MEIS1 level is
* Correspondence: jpgao@163.com
1Department of Urology, Chinese PLA Medical School/Chinese PLA General
Hospital, Beijing 100853, People’s Republic of China
Full list of author information is available at the end of the article
© The Author(s). 2017 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Zhu et al. BMC Cancer  (2017) 17:176 
DOI 10.1186/s12885-017-3155-2
inversely correlated with tumor metastasis and tumor sta-
ging of esophageal squamous cell carcinoma [14]. Xu et al
showed that MEIS1 would interact with Hox (homeobox
protein family) and Pbx1 (pre-B-cell leukemia homeobox
1) [15]. Our previous work also indicated that MEIS1 is a
negative regulator of androgen receptor (AR) pathway
[16]. To unmask thorough roles by which MEIS1 affect
cancer physiology, more studies should be done.
The ccRCC is one of the most common malignancies,
and it is the second leading cause of death among patients
suffering from urologic tumors [17, 18]. Nowadays, partial
nephrectomy is the most effective treatment for local
ccRCC [18]. As to chemotherapy and radiotherapy, the
prognosis of advanced metastatic ccRCCs still remains
very poor because tumor tissue has low sensitivity to those
therapeutic agents [17–20]. Although certain kinase inhib-
itors have been used in clinical application, such as sorafe-
nib and sunitinib, several problems have been raised
during recent trials, i.e. the risk of adverse events and un-
anticipated efficacy-loss, which may due to the off target
effects of current agents [19, 20]. Therefore, it is of great
importance to identify novel molecular targets for ccRCC
treatment.
In this study, we find that MEIS1 is less expressed in
some ccRCC cell lines and ccRCC specimens than in
non-tumor kidney cells and specimens. Overexpression
of MEIS1 significantly inhibits cell survival and induces
cell cycle G1/S phase arrest of ccRCC cells 786-O and
Caki-1. Furthermore, we demonstrate that reestablish-
ment of MEIS1 expression in high aggressive ccRCC cell
line Caki-1 leads to dramatic in vitro cell invasion and
migration reduction and decreased EMT process.
Moreover, overexpression of MEIS1 also inhibits in vivo
growth of Caki-1 cells in mouse model.
Methods
Plasmids and adenovirus vector preparation
The MEIS1 expression vector or its small interfering RNA
(siRNA) was as previously described [16]. Adenovirus vec-
tors of MEIS1 were generated following the methods as
described by Niu et al. [21]. Briefly, full length cDNA of
Meis1 gene was cloned into pShuttle-CMV vector. Then,
pAdEasy-1 vector and pShuttle-Meis1 vector was co-
transformed into BJ5183 cells to produce the recombinant
adenovirus vector pAd-control or pAd-MEIS1. For pack-
aging step, pAd-control or pAd-MEIS1 was transfected into
AD-293 cells and then purified with a cesium chloride gra-
dient. All vectors were confirmed by Sanger sequencing.
Cell culture and reagents
Human ccRCC cell lines 786-O or Caki-1 (a high meta-
static cell line), and non-tumor cell lines HEK293 (a human
embryonic kidney cell line) or HKC (a human kidney non-
tumor cell line) were as previously described [18]. 786-O,
Caki-1 and HKC cells were cultured in complete DMEM
(Invitrogen, Carlsbad, CA, USA), and HEK293 was cultured
in RPMI-1640 medium (Invitrogen, Carlsbad, CA, USA) in
a sterile incubator maintained at 37 °C with 5% CO2.
Cell growth and colony formation assays
For measuring proliferation, Caki-1 or 786-O cells,
which were infected with Ad-control or Ad-MEIS1, were
seeded in 96-well plates (Corning, NY, USA), incubated
for 1, 2, 3 and 4 days, and the cells were analyzed for
MTT assays [22]. HKC cells were transfected with
siRNA of MEIS1 and then harvested for MTT analysis.
For colony formation, infected ccRCC cells were
seeded in 6-well plates at 500 cells per well [23]. Two to
four weeks later, colonies were fixed with 4% parafor-
maldehyde and stained with 0.5% (W/W) crystal violet
(diluted in phosphate buffer saline, PBS) for 30 min.
Next, cells were harvested and measured by a multifunc-
tional micro-plate reader at 546 nm. The relative colony
number (relative survival cell number) =O.D. 546 ad-
ministration group / O.D. 546 control group. HKC cells,
which were transfected with siRNA of MEIS1, were also
measured by colony formation assays.
Cell cycle analysis
Cell cycle was carried out by flow-cytometry following
the instructions as previously described by Chen et al
[24]. ccRCC cells, which were infected with Ad-control
or Ad-MEIS1, were fixed in 70% ethanol for 18-24 h.
Next, cells were washed with pre-cold PBS for three
times and incubated with RNase A (0.2 mg/mL) diluted
in pre-cold PBS. Then, PI (propidium Iodide) was added.
Samples were analyzed by FACScalibur Flow Cytometer
(Becton Dickinson, Bioscience, USA).
Cell death analysis
Caki-1 or 786-O cells, which were infected with Ad-control
or Ad-MEIS1, were harvested and labelled with PI and
FITC-Annexin V according to the manufacturer’s instruc-
tions (Becton Dickinson, Biosciences, USA). A minimum of
2000 events for each sample were collected and analyzed
using a FACScalibur Flow Cytometer (Becton Dickinson,
Biosciences, USA).
Real-time PCR (qPCR)
Total RNA samples of cells or clinical specimens were
obtained by previously [18, 25]. The qPCR was performed
according to the manufacturer’s instructions (Applied
Biosystems, Foster City, CA, USA) using total RNA sample
as templates. The primers used to amplify MEIS1 expres-
sion are: forward: 5’-TCCCAA AGTAGCCACCAATATC-
3’; and reverse: 5’-CTGTATCTGTGCCAAC TGCTT-3’
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Anchorage-independent growth
Caki-1 or 786-O cells, which were infected with Ad-
control or Ad-MEIS1, were plated into 6-well plates (1000
cells per well) (Corning, Corning, NY, USA), with a bot-
tom layer of 1.0% low melting temperature agar in DMEM
and a top layer of 0.3% agar in DMEM. Colony number
was manifested as the mean ± SD of three independent
experiments scored after 3-4 weeks of growth [26].
Transwell migration assays (in vitro invasion or migration)
Caki-1 cells, which were infected with Ad-control or
Ad-MEIS1, were analyzed by transwell migration assays
performed in 24-well plates chamber (Corning, NY,
USA) by fitted with a polyethylene terephthalate filter
membrane with 8 μm pores. For invasion, the top cham-
bers was coated with 30 μl ECM (Extracellular matrix)
gel (Sigma, USA) diluted with serum free RPMI-1640 in
1:5 dilution for more than 4 h at 37 °C. Then, chambers
were filled with 0.2 ml of cells (5 × 105 cells per ml) in
serum-free medium, and the bottom chambers were
filled with 0.25 ml of medium with 10% FBS. The cells
were incubated in the trans-wells at 37 °C in 5% CO2 for
12 h. For migration, the cells were incubated in cham-
bers without ECM coated. After 10-15 h (for invasion)
or 4-6 h (for migration), chamber membrane was fixed
with 4% paraformaldehyde and stained with crystal vio-
let. The relative invading cells were measured according
to the instructions provided [27, 28]. Values were pre-
sented as the mean ± SD of triplicated experiments.
Antibodies and western blot
Antibodies against MEIS1, Cyclin D1, Cycline A, cIAP1/2,
Survivin, E-cadherin, N-cadherin, Vimentin, BAX and
GAPDH were obtained from Santa Cruz Biotechnology
(Santa Cruz Biotech, CA, USA). Polyclonal IgG conju-
gated with horseradish peroxidase (HRP) was obtained
from Sigma (St. Louis, MO, USA). Total protein samples
were performed by SDS-PAGE and trans-printed to poly-
vinylidene fluoride (PVDF) membranes (Millipore,
Billerica, MA). Then, membranes were blocked with 5%
BSA in TBST buffer and then incubated 2 h at 37 °C with
primary antibody against MEIS1 (1:1000), Cyclin D1
Fig. 1 MEIS1 expresses in ccRCC cells 786-O and Caki-1 and kidney non-tumor cells HEK293, and HKC. a Total protein extracted from the indicated cell
lines were analyzed by WB. GAPDH was chosen as a loading control. b The relative protein level was shown as mean ± SD from three independent
experiments with similar results. c The mRNA level of Meis1 in 10-paired colorectal cancer and matched adjacent was determined by real-time RT-PCR.
The ccRCC cells, Caki-1 (d) or 786-O (e) were infected with Ad-control or Ad-MEIS1. The expression of MEIS1 in ccRCC cells were shown as photographs
or relative expression level. *p < 0.05 versus with cells infected Ad-control or Ad-MEIS1
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(1:500), Cyclin A (1:500), cIAP-1 (1:1000), cIAP-2 (1:1000),
Survivin (1:2000), E-cadherin (1:1000), N-cadherin (1:1000),
Vimentin (1:2000), BAX (1:500) and GAPDH (1:5000)
diluted in TBST containing 5% BSA and subsequently
washed three times in TBST for 5 min each. Then mem-
branes were incubated with the HRP-conjugated second-
ary antibodies (1:5000) after being washed three times in
TBST for 5 min each. At last, blots were developed with
enhanced chemiluminescence reagents by X-ray films.
The blots were performed on three experiments with
similar results.
In vivo analysis
In vivo nude mice model was created via xenotransplant-
ation of Caki-1 cells into 4-5 week-old nude mice (6 ani-
mals per group) [29]. Caki-1 cells, which were infected
with Ad-control or AD-MEIS1, were injected with 5 × 105
cells re-suspended in PBS or normal/physiological saline.
Tumor volumes were measured every week by measuring
length and width. Volumes of tumor were calculated:
(width2 × length) / 2 [29]. Animal Experiment Committee
of General Hospital of Chinese PLA approved all proto-
cols for treating animals, and the in vivo studies were
Fig. 2 MEIS1 attenuates ccRCC cells proliferation or survival. Caki-1 (a) or 786-O (b) cells infected with Ad-control, Ad-MEIS1 or the parental cells were
grown in regular medium and harvested at indicated time points. Cell number was determined by MTT. Then, colony formation for Caki-1 (c) and
786-O (d) cells infected with Ad-control or Ad-MEIS1 were measured. All values were shown as photograph (c, d) or mean ± SD (e, f) of triplicate
measurements with similar results. *p < 0.05 versus with parental cells or cells infected Ad-MEIS1, *p < 0.05 versus with Ad-control or Ad-MEIS1
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carried out in accordance with the U.K. Animals (Scien-
tific Procedures) Act, 1986 and associated guidelines.
Statistical analysis
The WB results were analyzed by the ALPHA INNOTECH
analysis software. The relative expression level was calcu-
lated: (indicated group protein expression level/loading
control expression level)/(control group protein expression
level/loading control expression level). All statistical signifi-
cance analyses were performed using SPSS statistical soft-
ware. P-value of <0.05 was considered statistically significant.
Statistical significance in cell growth assays was analyzed by
Bonferroni correction with or without two-way ANOVA.
Results
MEIS1 is expressed in ccRCC cell lines and tissues
First, the endogenous level of MEIS1 in ccRCC and non-
tumor kidney cells was examined by WB. As shown in
Fig. 1a, b, high level of MEIS1 was detected in non-
tumor cell line, HEK-293 and HKC. In contrast, MEIS1
expression in ccRCC cell lines Caki-1 and 786-O was
much lower. Next, the expression of MEIS1 in ccRCC
clinical specimens was detected (Fig. 1c). Ten paired
ccRCC/non-tumor cDNA samples were analyzed by
qPCR. The endogenous level of MEIS1 was significantly
lower in ccRCC samples than in adjacent non-neoplastic
clinical specimens (Fig. 1c). Our data from cell lines and
clinical specimens suggest that loss of MEIS1 may play a
role in the progression of ccRCC.
Next, to further study the detailed functions of MEIS1
in ccRCC, we generated MEIS1 expressing adenoviral
vectors. Ad-control carries out the empty vector and
Ad-MEIS1 contains full length coding sequence of Meis1
gene. Caki-1 or 786-O cells were infected with Ad-control
or Ad-MEIS1. The protein level of MEIS1 was signifi-
cantly increased upon Ad-MEIS1 infection (Fig. 1d, e).
MEIS1 suppresses ccRCC cells proliferation
To test whether MEIS1suppresses ccRCC proliferation, we
performed MTTassay. Caki-1 and 786-O cells that were in-
fected with Ad-MEIS1 grew slower than those infected with
Ad-controls or their parental cells (Fig. 2a, b). Since there
was no significant difference between the parental cells and
cells infected with Ad-controls (Fig. 2a, b), our data suggest
that MEIS1 overexpression inhibits ccRCC cell growth.
Moreover, colony formation assay (CFAs) showed that col-
ony number was reduced in MEIS1 overexpressing Caki-1
or 786-O cells than in control cells (Fig. 2c-f). Together,
these results reveal that MEIS1 may attenuate the prolifera-
tion and colony formation of ccRCC cells.
Next, to confirm MEIS1’s function, we knockdown
MEIS1 in HKC cells; HKC is a normal human kidney
Fig. 3 Down-regulation of MEIS1 via siRNA promotes HKC proliferation or survival. HKC cells (a) infected with Ad-control or Ad-MEIS1 were grown
in regular medium and harvested at the indicated time points. Cell numbers were determined by MTT assay at 490 nm. The expression of MEIS1
was identified by WB (b, c). Next, colony formation for HKC cells (d) was measured. All values were shown as photograph (d, e) or mean ± SD (f)
of triplicate measurements with similar results. *p < 0.05 versus with Ad-control or Ad-MEIS1
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cell line highly expressing endogenous MEIS1. As
shown in Fig. 3, knockdown of MEIS1 via its siRNA
enhanced the proliferation (Fig. 3a-c), colony number
and size (Fig. 3d-f ) of HKC cells. These results con-
firmed that MEIS1 negatively regulates cell growth
and proliferation.
MEIS1 decreases the anchorage-independent growth of
ccRCC cells
To further examine tumor-suppressing activity of
MEIS1, soft-agar assay was performed to examine the
anchorage-independent growth of ccRCC cells. Our
results indicated that MEIS1 overexpression inhibited
Fig. 5 MEIS1 induces non-apoptotic cell death of ccRCC cells. a, b Representative flow-cytometer of cells stained with Annexin V and PI in (a)
Caki-1 or (b) 786-O cells infected with Ad-control or Ad-MEIS1. Data were also shown as mean ± SD of three experiments with similar experiments.
*p < 0.05 versus with Ad-control or Ad-MEIS1
Fig. 4 MEIS1 inhibits anchorage-independent growth of ccRCC cells. Caki-1 (a) or 786-O (b) cells, which were infected with Ad-control or Ad-MEIS1,
were analyzed by soft agar. Results were shown as photograph or mean ± SD of triplicate measurements with similar results. *p < 0.05 versus with
Ad-control or Ad-MEIS1
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anchorage-independent growth of Caki-1 and 786-O
cells (Fig. 4a,b).
MEIS1 overexpression induces non-apoptotic death of
ccRCC cells
Next, we examined whether MEIS1 participates in regulat-
ing cell death of ccRCC. As shown in Fig. 5, the propor-
tion of non-apoptotic death increased after overexpressing
MEIS1, from 3.12% to 19.58% (Caki-1), or 4.10% to 21.59
(786-O) (Fig. 5a, b).
To explain how MEIS1 regulates non-apoptotic cell
death, we examined central components in this process. As
shown in Fig. 6, overexpression of MEIS1 in Caki-1 cell
reduced the expression of pro-survival proteins cIAP-1
(cellular inhibitor of apoptosis 1), cIAP-2 (cellular inhibitor
of apoptosis 2) and Survivin (Fig. 6a). MEIS1 also increased
the protein level of pro-apoptosis regulator BAX. Similar
results were obtained from 786-O cells (Fig. 6b). These
results demonstrate that the inhibitory activity of MEIS1
on ccRCC cells proliferation and survival may depend on
its regulation on those pro-apoptosis related proteins.
MEIS1 overexpression induces ccRCC cell cycle arrest at
G1/S transition
To further elucidate the mechanism by which MEIS1 nega-
tively regulates ccRCC cells growth, we examined the effect
of MEIS1 on cell cycle. Overexpression of MEIS1 in Caki-1
cells resulted in a reduction in proportion of cells in S
phase (from 25.07% to 14.07%) and G2/M phase (from
14.85% to 3.25%) but an increase in proportion of cells in
G0/G1 phase (from 58.25% to 75.68%) (Fig. 7a). Similar re-
sults were also obtained from 786-O cells (Fig 7b). MEIS1
overexpression increased the proportion of 786-O cells in
G0/G1 phase (from 56.25% to 80.68%), and decreased S
phase cells (from 26.07% to 12.07%) or G2/M cells (from
17.67% to 7.25%). These data indicated that MEIS1 could
induce ccRCC cell cycle arrest at G1/S transitions.
To investigate how MEIS1 regulates cell cycle, we tested
whether MEIS1 modulates the endogenous expression of
positive G1/S transition regulators, Cyclin D1 and Cyclin
A. As shown in Fig. 8, MEIS1 overexpression decreased
Cyclin A and Cyclin D1 in ccRCC cells (Fig. 8a, b). Taken
together, these data suggest that MEIS1 induces ccRCC
Fig. 6 MEIS1 reduces the protein level of pro-survival and enhances the expression of pro-apoptosis regulator. Caki-1 (a) or 786-O (b) cells were
infected with Ad-control or Ad-MEIS1. Then, cells were harvested for WB. Protein level of pro-survival regulators cIAP-1, cIAP-2 or Survivin and
pro-apoptosis regulator BAX was detected by antibodies. GAPDH was chosen as loading controls. Relative protein level is shown as mean ± SD of
three experiments with similar results. *p < 0.05 versus with Ad-control or Ad-MEIS1
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cell cycle arrest at G1/S transitions via down-regulating
cyclin A and cyclin D1.
MEIS1 overexpression inhibits in vitro invasion and
migration of ccRCC cells with decreased EMT
Transwell migration assay (TMA) was used to assess the
effect of MEIS1 on ccRCC cells in vitro invasion and mi-
gration. Our results indicated that overexpression of
MEIS1 attenuates in vitro invasion (Fig. 9a) and migra-
tion (Fig. 9b) of the highly aggressive Caki-1 cells. More-
over, MEIS1 overexpression increased the expression of
epithelial marker E-cadherin and decreased that of
N-cadherin and Vimentin, two mesenchymal markers
(Fig. 10a, b). These results, which were in consistent
with TMA experiments, suggested that MEIS1 overex-
pression could inhibit the in vitro invasion and migra-
tion of Caki-1 cells via disrupting EMT process.
MEIS1 overexpression attenuates in vivo growth of Caki-1
cells in nude mice model
The effect of MEIS1 overexpression on in vivo growth of
Caki-1 cells was examined in a xenograft nude mice
model (Fig. 11). Infection of Ad-MEIS1 could signifi-
cantly shrink the tumor volume or weight of Caki-1
compared with Ad-control. Thus, MEIS1 attenuates in
vivo growth of Caki-1 cells in nude mice model.
Fig. 7 MEIS1 induces the cell cycle arrest at G1/S in ccRCC cells. a, b Cell cycle of Caki-1 (a) or 786-O (b) cells infected with Ad-control or Ad-MEIS1
were detected by flow-cytometry. The proportion of cells in each cell cycle phase was shown (a, b). The G0/G1 cells in Caki-1 (c) or 786-O cells (d) was
also shown as mean ± SD of three experiments with similar results. *p < 0.05 versus with Ad-control or Ad-MEIS1
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Discussion
For the first time, our study discovers that MEIS1 may
function as a tumor suppressor in ccRCC. First, MEIS1
expression is reduced in ccRCC tissues or cell lines; sec-
ond, overexpression of MEIS1 suppresses proliferation,
colony formation and anchorage independent growth of
ccRCC cells; third, MEIS1 overexpression induces cell
cycle G1/S arrest and non-apoptotic cell death of ccRCC
cells. At molecular level, MEIS1 overexpression de-
creases the expression of pro-survival regulators cIAP-1,
Fig. 8 MEIS1 reduces the positive G1/S transition regulators, Cyclin D1 and Cyclin A. Representative WB for Cyclin D1 or Cyclin A in MEIS1 overexpressing
Caki-1 (a) or 786-O (b) cells. Data were also shown as mean ± SD of three experiments with similar results. *p< 0.05 versus with Ad-control or Ad-MEIS1
Fig. 9 MEIS1 inhibits metastasis of high aggressive ccRCC cells Caki-1. Caki-1 cells, infected with Ad-control or Ad-MEIS1, were analyzed by
transwell formation assays. Invasion (a) or migration (b) was shown as photograph or mean ± SD of triplicate measurements with similar results.
*p < 0.05 versus with Ad-control or Ad-MEIS1
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cIAP-2 and Survivin; whereas increases pro-apoptosis
protein BAX. Further, MEIS1 overexpression can disrupt
the metastasis of Caki-1 cells and leads to decreased
EMT process. These findings expand our knowledge
about MEIS1 and suggest that MEIS1 may play an
important role in the development and progression of
ccRCC and this work may carry out its potential applica-
tion in ccRCC treatment.
Cell cycle checkpoints protect genomic integrity [30].
Alterations of cell cycle related proteins, including Cyc-
lin or CDK, would be a hallmark for multiple of human
cancers [31]. The transformation of human cancers usu-
ally accompanies with the deregulation of G1/S cell cycle
checkpoint controls [32]. Cyclins and their associated
CDKs are the central machinery that governs cell cycle
progression [21]. Of the various cyclin/CDK complexes
implicated in cell cycle progression, cyclin D1/CDK4/6
and cyclin D1/CDK4/6 and cyclin A/CDK1 are of great
interest, because they mediate G1/S transition [30–32].
In this study, we show that, in ccRCC, MEIS1 overex-
pression arrests cell cycle at G1/S transition, along with
reduced expression of cyclin D1 and cyclin A. Previous
reports showed that MEIS1 controls cells proliferation
via regulating cyclinD1 and c-MYC level [33–35]. These
results indicated that MEIS1 could be an important cell
cycle regulator and attenuate cell proliferation via dis-
rupting cell cycle progression. CDK inhibitors, e.g. P15,
P16, P21, P27 or Rb may inhibit the activity of cyclin/
CDK complexes and be growth inhibitor [21]. Down-
regulation of these inhibitors often associates with poor
Fig. 10 MEIS1 inhibits EMT process. Caki-1 cells were infected with Ad-control or Ad-MEIS1. The expression of epithelial marker E-cadherin and
two mesenchymal markers, N-cadherin and Vimentin was detected by antibodies (a). Relative protein level is shown as the mean ± SD of three
experiments with similar results (b). *p < 0.05 versus with Ad-control or Ad-MEIS1
Fig. 11 MEIS1 inhibits in vivo growth of Caki-1 cells. Caki-1 cells were infected with Ad-control or Ad-MEIS1. Next, cells were injected in to BALB/
c nude mice. The effect of MEIS1 on Caki-1 in vivo growth was showed as photograph (a), tumor volumes (b) or tumor weight (c). *p < 0.05
versus with Ad-control or Ad-MEIS1
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prognosis of human cancers, thus it is valuable to fur-
ther study whether MEIS1 regulates expression of CDK
inhibitors in the future.
Recent publications provided clues that MEIS1 may par-
ticipate in tumor progression, including leukemogenesis,
NSCLC or nephroblastoma progression [36–38]. Among
these works, MEIS1 is well-defined in modulating AML
and prostate cancer progress. Also, MEIS1 would function
as a tumor suppressor in some other kinds of human
cancer [11–14]. It promotes the differentiation and sup-
presses the proliferation of non-tumor prostate epithelial
cells [3, 13]. Decreased expression of MEIS1 is predicted
as worse overall survival (OS) while elevated level of
MEIS1 was associated with improved OS in prostate can-
cer [3, 13]. Our previous work also indicated that MEIS1
functions as a negative AR regulator and inhibits the
ligand-dependent growth of certain kinds of prostate can-
cer [16]. Based on the previous discovery of MEIS1, to fur-
ther reveal its function and develop potential therapy in
human cancer treatment are accessible. This work dis-
covers, for the first time, MEIS1 as a tumor suppressor in
ccRCC. In this work, MEIS1 overexpression could repress
in vitro invasion and migration of high aggressive ccRCC
cell line Caki-1 and lead to decreased EMT, the critical
step mediating cancer metastasis. Since invasion and
migration are main features of malignancies, our data
reveal that MEIS1 overexpression could be a potential
approach to improve the cancer prognosis of advanced
metastatic ccRCC.
Conclusions
In summary, MEIS1 functions as a suppressor in ccRCC
progression, supported by the fact that endogenous
expression of MEIS1 reduces in ccRCC cells lines speci-
mens Overexpression of MEIS1 significantly inhibits
proliferation and apoptosis of ccRCC cells. These find-
ings would help us to understand more about MEIS1 in
cancerous cell proliferation and also provide a new
potential approach to ccRCC treatment.
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